The GLP-1 marketing compliance timeline, 2022 to 2026

The rules for marketing GLP-1 medications have changed four times since semaglutide went mainstream. Practices that built their acquisition stack in 2023 are still running copy that would draw a regulator’s attention in 2026. Here is the timeline, what changed at each point, and the compliance posture that holds up today.

This is a timeline, not legal advice. Every practice marketing GLP-1s should have healthcare counsel review ad copy and treatment-page language. The patterns below are what we have seen across the Macbach book, what we have watched trip up practices that didn’t change, and what we build into every AdsPRO engagement in the weight-loss vertical.

2022: The category opens.

Novo Nordisk’s semaglutide (marketed as Wegovy for weight loss and Ozempic for type-2 diabetes) cleared FDA approval for weight management in June 2021 for adults with obesity. By mid-2022, demand had far outpaced supply. The FDA declared semaglutide a shortage drug, which unlocked 503A and 503B compounding pharmacies to produce compounded versions legally.

What practices did: built GLP-1 programs around compounded semaglutide at 40 to 70 percent of Novo Nordisk’s price. Telehealth startups launched with aggressive direct-to-consumer marketing. Independent clinics followed. Ad platforms (Google, Meta) allowed GLP-1 marketing with standard pharmaceutical-adjacent restrictions.

What we told clients: the shortage status was not going to last. Build the program around the compounded option for the immediate term, but design the patient-facing messaging to survive the transition. Emphasize clinical supervision, medication sourcing from legitimate pharmacies, and patient-selection standards that would hold up when (not if) the regulatory environment tightened.

2023: LegitScript tightens, Meta follows.

Spring 2023: Meta (Facebook and Instagram) began requiring LegitScript certification for any advertiser promoting prescription medications, including GLP-1s. Practices without LegitScript certification found their campaigns rejected overnight. Google had required LegitScript for some pharmacy advertising for years; Meta’s move closed the last major platform gap.

LegitScript certification takes 45 to 90 days end to end and costs $1,995 per year plus the $995 one-time application fee. It requires proof of state licensure, pharmacy board registration where applicable, physician oversight documentation, and protocols for patient eligibility, prescription sourcing, and adverse-event reporting. Practices that waited to apply until their ads were rejected lost two to three months of paid acquisition while the application processed.

Also in 2023: state attorneys general in several states (California, New York, Massachusetts, and others) began public scrutiny of telehealth-sourced GLP-1 marketing. The concern was less the medication and more the pattern of asynchronous prescribing without meaningful patient evaluation. Practices with in-person or real-time telehealth consultations stayed out of the crosshairs; practices running automated intake flows ending in a prescription drew state regulator attention.

What we told clients: LegitScript is table stakes. Budget it. The longer-term compliance play is documenting patient selection, eligibility screening, and ongoing monitoring in a way a regulator could audit. Content that emphasized “easy” or “quick” prescribing started to read as a risk signal rather than a feature.

2024: Shortage resolution, compounded space narrows.

In October 2024, the FDA declared tirzepatide (Eli Lilly’s Mounjaro and Zepbound) no longer in shortage, triggering a 60- to 90-day wind-down period for compounded tirzepatide. Semaglutide’s shortage status followed a similar path, with the FDA removing it from the drug shortage list in February 2025.

The legal implication: 503A and 503B compounding pharmacies lost the regulatory basis for producing these compounded GLP-1s. Practices that had built their programs around compounded semaglutide or tirzepatide had to pivot to branded medications (at roughly 2x to 4x the patient cost) or to different compounded formulations (peptide blends that remained legal under different rules).

Marketing-side fallout: claims in existing ad creative about “affordable semaglutide” or “compounded alternatives” became risky. Some claims became factually outdated (the compounded option the ad referenced was no longer legal); others remained factually correct for different formulations but risked misleading patients about what they would actually be prescribed.

What we told clients: audit every line of live ad copy and every paragraph of treatment-page content against the new legal reality. Remove price-comparison framing against branded medications unless the comparison is explicitly for peptide alternatives. Replace “compounded semaglutide” language with specific product names and specific sourcing. Practices that hadn’t re-written in 90 days were operating in a gray zone.

2025: Enforcement accelerates.

Through 2025, FTC enforcement actions and state-level pharmacy board actions against GLP-1 marketers ramped. The targets were not the well-run clinical practices; they were the aggressively-marketed, thin-oversight telehealth operators. But the collateral effect was broader scrutiny across the entire category.

Specific patterns drew attention: claims about specific weight-loss amounts (“lose 20 pounds in 3 months”), before-and-after photos without proper disclosure, testimonials without the required FTC-mandated disclaimers, any marketing implying that the patient would definitely be approved for a prescription (implying asynchronous prescribing), and comparisons to branded products in ways that could be read as claiming compounded equivalence.

Ad platforms also tightened. Google disapproved GLP-1 ads with specific weight-loss claims at a higher rate in 2025 than in 2024. Meta added a secondary review layer for any pharmaceutical-adjacent creative featuring body imagery. Practices that had built their creative libraries around body-comparison imagery had to rebuild.

What we told clients: creative needs to be rebuilt around clinical positioning rather than outcome claims. The ads that work in 2025-2026 emphasize physician-led evaluation, medical-grade monitoring, and cardiometabolic framing rather than weight-loss-amount framing. Counterintuitively, this clinical positioning often performs better than outcome-claim creative because it reaches a more serious patient pool and converts to a higher-LTV membership.

The 2026 compliance posture that holds up.

This is the posture we build into every AdsPRO engagement in the weight-loss vertical. It has held up through four rounds of policy shifts; it will hold up through the next round too.

LegitScript certification, current. Every practice running any paid acquisition for any prescription medication category. Budget it as a fixed cost, renew annually, keep the documentation current.

Real patient evaluation, documented.Synchronous telehealth minimum. In-person consultations where practical. Documented eligibility screening before prescription. Documented ongoing monitoring between prescriptions. This is both clinically correct and defensively correct; it is the single largest factor separating the practices that stayed out of the 2025 enforcement wave from the ones that didn’t.

Specific medication language, not generic.Treatment pages should name the specific products prescribed (semaglutide vs. tirzepatide vs. specific peptide formulations), specify pharmacy sourcing, and avoid any framing that could be read as promoting a compounded version of a non-shortage medication. “Compounded GLP-1” without further specificity is a 2022 phrase that should not appear on a 2026 site.

No outcome claims, no comparison claims.Remove specific weight-loss amounts from ad copy and treatment pages. Remove “affordable alternative to Wegovy” style framing unless the product referenced is genuinely and legally a separate formulation. Use clinical endpoints (BMI reduction, cardiometabolic markers, pre-diabetes reversal) instead of aesthetic outcomes.

FTC-compliant testimonials. Patient testimonials require disclosure: that the patient is a real patient, that individual results vary, that compensation (if any) was received. Before-and-after photos need disclosure of treatment timeframe, specific medication used, and disclaimer language. Most practices either under-document or over-claim; the middle ground takes work to get right.

Server-side Conversion API for paid. Not compliance-specific, but operationally critical. iOS privacy changes have eroded pixel-based conversion tracking; practices without server-side CAPI are optimizing on incomplete signals. This is a Dominance-tier feature in AdsPRO and the thing that separates practices running paid on guessed ROAS from practices running paid on measured ROAS.

What we expect in 2026 and 2027.

Three likely vectors. First: continued state-by-state attorney general scrutiny of telehealth-first GLP-1 models. The patchwork-state nature makes this hard to navigate for multi-state operators; single-state clinical practices are insulated.

Second: FDA review of the peptide compounding space. Semaglutide and tirzepatide are off the shortage list; the peptide formulations that compounding pharmacies have pivoted to (tirzepatide-plus-vitamin-B12 blends, semaglutide-plus-cyanocobalamin, retatrutide-adjacent formulations) are still largely legal, but the legal basis is narrower than the 2022-2024 shortage era. Expect tightening here.

Third: Medicare and commercial-payer expansion. As branded GLP-1 coverage expands, the cash-pay market will shift toward patients who don’t qualify for coverage (BMI thresholds, comorbidity requirements) and toward patients who want the accessibility cash-pay provides (no PCP gatekeeping, no prior authorization). The marketing positioning pivots from “affordable alternative” to “accessibility alternative.”

Practices that built their GLP-1 programs around compounded-price-point positioning will need to rebuild around access-and-clinical-depth positioning. The ones that have already started that rebuild are several quarters ahead.

The honest summary: GLP-1 compliance is not one rule to learn. It is a moving target that has changed substantively four times in four years and will change again. The practices that win long-term are not the ones that memorize the current rules; they are the ones that build clinical, operational, and marketing depth that survives the next rule change.